JW (Cayman) Therapeutics Co (HKSE:02126) Pretax Margin % : % (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. JW (Cayman) Therapeutics Co's Pre-Tax Income for the six months ended in Dec. 2023 was HK$0.0 Mil. JW (Cayman) Therapeutics Co's Revenue for the six months ended in Dec. 2023 was HK$0.0 Mil. Therefore, JW (Cayman) Therapeutics Co's pretax margin for the quarter that ended in Dec. 2023 was %.

The historical rank and industry rank for JW (Cayman) Therapeutics Co's Pretax Margin % or its related term are showing as below:

HKSE:02126' s Pretax Margin % Range Over the Past 10 Years
Min: -2280.5 Med: -580.73 Max: -441.74
Current: -476.65

HKSE:02126's Pretax Margin % is ranked worse than
64.85% of 1027 companies
in the Biotechnology industry
Industry Median: -154.52 vs HKSE:02126: -476.65

JW (Cayman) Therapeutics Co Pretax Margin % Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Pretax Margin % Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pretax Margin %

Get a 7-Day Free Trial

-2,280.50

-580.73

-441.74

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Pretax Margin %	Get a 7-Day Free Trial						-1,369.07	-650.32	-523.09	-433.57	-

Competitive Comparison of JW (Cayman) Therapeutics Co's Pretax Margin %

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Pretax Margin % falls into.

JW (Cayman) Therapeutics Co Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

JW (Cayman) Therapeutics Co's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-840.018	/	190.16
	=	-441.74 %

JW (Cayman) Therapeutics Co's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	0
	=	%

JW (Cayman) Therapeutics Co (HKSE:02126) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

JW (Cayman) Therapeutics Co Pretax Margin % Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

JWCTF:USA

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

Executives

Li Dan	2202 Interest of your spouse
Li Yiping James	2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd.	2501 Other
Bristol-myers Squibb Company	2201 Interest of corporation controlled by you
Celgene Corporation	2201 Interest of corporation controlled by you
Juno Therapeutics, Inc.	2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd.	2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines